LLY

1,043.27

-0.6%↓

JNJ

203.34

+0.48%↑

ABBV

229.85

-0.59%↓

UNH

313.29

+1.59%↑

AZN

88.75

0%↓

LLY

1,043.27

-0.6%↓

JNJ

203.34

+0.48%↑

ABBV

229.85

-0.59%↓

UNH

313.29

+1.59%↑

AZN

88.75

0%↓

LLY

1,043.27

-0.6%↓

JNJ

203.34

+0.48%↑

ABBV

229.85

-0.59%↓

UNH

313.29

+1.59%↑

AZN

88.75

0%↓

LLY

1,043.27

-0.6%↓

JNJ

203.34

+0.48%↑

ABBV

229.85

-0.59%↓

UNH

313.29

+1.59%↑

AZN

88.75

0%↓

LLY

1,043.27

-0.6%↓

JNJ

203.34

+0.48%↑

ABBV

229.85

-0.59%↓

UNH

313.29

+1.59%↑

AZN

88.75

0%↓

Home・Aandelen Lijst・Ventyx Biosciences Inc

Ventyx Biosciences Inc

Open

9.58 0.21

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

9.31

Max

9.97

Belangrijke statistieken
By Trading Economics
Inkomsten	4.2M -23M
Winstmarge	-2,027.003
Werknemers	83
EBITDA	6.6M -23M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+40.35% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	91M 678M
Vorige openingsprijs	9.37
Vorige sluitingsprijs	9.58

Ventyx Biosciences Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

19 nov 2025, 23:36 UTC

Populaire aandelen

Stocks to Watch: Nvidia, Kulicke & Soffa, Regeneron

19 nov 2025, 22:13 UTC

Winsten

Acquisities, Fusies, Overnames

Palo Alto Networks to Buy Chronosphere for $3.35 Billion, Posts Higher 1Q Revenue -- Update

19 nov 2025, 21:55 UTC

Belangrijke Marktbewegers

Amgen Lung Cancer Drug Gets Full Approval From FDA

19 nov 2025, 21:43 UTC

Acquisities, Fusies, Overnames

Palo Alto Networks to Buy Chronosphere for $3.35 Billion

19 nov 2025, 23:55 UTC

Marktinformatie

Gold Rises on Possible Investment Demand -- Market Talk

19 nov 2025, 23:54 UTC

Marktinformatie

BHP Vicuna JV Offers Significant Copper Output, At a Cost -- Market Talk

19 nov 2025, 23:47 UTC

Winsten

Lenovo Group 2Q EPS $2.52 >0992.HK

19 nov 2025, 23:46 UTC

Winsten

Lenovo Group: Delivered Double-Digit Yr-on-Yr Rev Growth Across All Main Business Groups and Sales Geographies >0992.HK

19 nov 2025, 23:45 UTC

Winsten

Lenovo Group 2Q Rev $20.5B >0992.HK

19 nov 2025, 23:42 UTC

Marktinformatie

Nikkei May Rise After Nvidia's Strong Earnings Soothe Investors' Nerves -- Market Talk

19 nov 2025, 23:42 UTC

Marktinformatie

Global Equities Roundup: Market Talk

19 nov 2025, 23:41 UTC

Winsten

Lenovo Group 2Q Adj Net $512.0M Vs. $409.0M >0992.HK

19 nov 2025, 23:41 UTC

Winsten

Lenovo Group 2Q Net $340.0M Vs. Net $359.0M >0992.HK

19 nov 2025, 23:40 UTC

Winsten

Lenovo Group 2Q Rev $20.45B Vs. $17.85B >0992.HK

19 nov 2025, 22:55 UTC

Winsten

Nvidia Profits Soar, Countering Investor Jitters on AI Boom -- 4th Update

19 nov 2025, 22:41 UTC

Winsten

Nvidia Profits Soar, Countering Investor Jitters on AI Boom -- 3rd Update

19 nov 2025, 22:30 UTC

Acquisities, Fusies, Overnames

CICC Seeks Trading Halt in Hong Kong, Shanghai Stock Exchange

19 nov 2025, 22:30 UTC

Winsten

Nvidia Profits Soar, Countering Investor Jitters on AI Boom -- 2nd Update

19 nov 2025, 22:30 UTC

Acquisities, Fusies, Overnames

CICC Plans to Acquire Brokerage Firms via Share-Swap Agreement

19 nov 2025, 22:27 UTC

Acquisities, Fusies, Overnames

China International Capital Plans to Acquire Brokerage Firms Cinda Securities, Dongxing Securities

19 nov 2025, 22:08 UTC

Winsten

ZTO Express (Cayman) 3Q Rev $1.67B >ZTO

19 nov 2025, 22:00 UTC

Winsten

Investors Cheer Blockbuster Nvidia Earnings -- WSJ

19 nov 2025, 21:58 UTC

Winsten

Acquisities, Fusies, Overnames

Palo Alto Networks to Buy Chronosphere for $3.35B, Posts Higher 1Q Rev -- Update

19 nov 2025, 21:52 UTC

Winsten

Nvidia Profits Soar, Countering Investor Jitters on AI Boom -- Update

19 nov 2025, 21:50 UTC

Marktinformatie

Winsten

Tech, Media & Telecom Roundup: Market Talk

19 nov 2025, 21:49 UTC

Marktinformatie

Winsten

Nvidia Quiets Investor Fears With Ballooning Demand -- Market Talk

19 nov 2025, 21:38 UTC

Winsten

Nvidia Profits Soar, Countering Investor Jitters on AI Boom -- WSJ

19 nov 2025, 21:28 UTC

Acquisities, Fusies, Overnames

Palo Alto Networks to Buy Chronosphere for $3.35B

19 nov 2025, 21:27 UTC

Acquisities, Fusies, Overnames

Exact Sciences Stock Jumps on Reported Deal Interest from Abbott Laboratories -- Barrons.com

19 nov 2025, 21:24 UTC

Winsten

Acquisities, Fusies, Overnames

Palo Alto Networks 1Q Next-Generation Security ARR $5.9 B >PANW

Peer Vergelijking

Prijswijziging

Ventyx Biosciences Inc Prognose

Koersdoel

By TipRanks

40.35% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 13.67 USD 40.35%

Hoogste 21 USD

Laagste 2 USD

Gebaseerd op 7 Wall Street-analisten die 12-maands prijsdoelen bieden voor Ventyx Biosciences Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

7 ratings

Buy

Hold

Sell

Gebaseerd op 7 analisten die aandelenratings hebben gegeven aan Ventyx Biosciences Inc - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Ventyx Biosciences Inc

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.